Drug interaction study in healthy men tests how bosentan changes levels of experimental BI 425809

NCT ID NCT05723874

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial enrolled 14 healthy men to see how taking bosentan (a drug for high blood pressure in the lungs) affects the amount of BI 425809 (iclepertin) in the blood. Participants took BI 425809 alone for 10 days, then both drugs together for 14 days. The study measured drug levels to understand the interaction, but did not test any treatment for a disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 425809 (iclepertin) and bosentan
What this could lead to: If successful, this study could help determine the correct dose of BI 425809 when taken with bosentan, improving safety and effectiveness for future patients.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels, not actual treatment effects, so results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Humanpharmakologisches Zentrum Biberach

Biberach, 88397, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.